Pharmaceutical Firms

Natco rallies 5%, nears 52-week high; what's driving pharma stock?

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals soars 9% in weak market on huge volumes

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

Indian pharma market grows 11% in Feb as Mounjaro tops drug sales

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Indian CDMOs expand capacity as demand for complex drug work rises

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.

Drugmakers may review shipment schedules to West Asia if conflict drags on

Indian drugmakers are reviewing shipment schedules and inventories for West Asia as escalating tensions threaten sea and air routes, raising freight costs and risking supply delays

Cipla, Kemwell form biologics JV to tap fast-growing biosimilars market

Cipla will hold 60% in the new JV with Kemwell Biopharma, aiming to develop, manufacture and commercialise biologics and biosimilars for global markets amid rising demand

Sai Life soars 25% in 5 weeks, hits record high in weak market; here's why

ICRA expects Sai Life Sciences to maintain strong growth momentum over the medium term on the back of a healthy growth outlook for the industry, good product mix and deepening customer engagement.

CDSCO modifies norms for testing permissions to speed up drug approvals

In a move aimed at speeding up approvals for new drugs, the government has changed the way testing permissions are granted, allowing companies to begin laboratory testing immediately after filing applications instead of waiting for detailed scrutiny. In an official circular, the country's apex drug regulatory authority, Central Drugs Standard Control Organization (CDSCO), said it has decided that "No Objection Certificate (NOC) for testing of drug samples at the designated laboratories (IPC, Ghaziabad; CDTL, Mumbai; CDL at CRI, Kasauli; or NIB, Noida) shall be issued immediately upon receipt of applications in the concerned division." Earlier, the regulator examined detailed specifications submitted by applicants before issuing permission for testing. These included "Type of formulation, dosage form, Critical Quality Attributes (CQAs), and general characteristics of the product," along with "Product development reports, forced degradation studies, and other relevant data, in ...

Morepen Labs wins ₹825 crore long-term CDMO deal with global drugmaker

Morepen Labs has secured a ₹825 crore multi-year CDMO mandate from a global pharma major, with supplies set to begin in 4-5 months and execution running through Q1 FY27

Morepen Labs wins ₹825 crore manufacturing contract from global drugmaker

Morepen Laboratories said supplies under the contract are expected to begin within the next four to five months, while execution is scheduled through the first quarter of the financial year 2026-27

Lupin settles US patent dispute with Astellas Pharma for $90 million

The settlement resolves Lupin's ‌pending litigation with Astellas and ​enables the company to continue marketing Mirabegron in the United States

Eyeing a growth pill: Pharma Inc calls for easier regulatory prescription

Industry says approval delays, weak clinical trial infra holding back sector

Sun Pharma to maintain disciplined approach for acquisitions: Chairman

Sun Pharma will maintain a disciplined approach when it comes to acquisitions in order to allow the business to grow organically while remaining attractive for shareholders, according to Chairman Dilip Shanghvi. The Mumbai-based drug major is also evaluating biosimilar segments, he stated. "I think the US continues to be an important part of our focus, specifically for innovative medicines," Shanghvi said when asked about the company's M&A strategy in an analyst call. The company is interested in selling innovative medicines globally, he added. "For emerging markets, we are looking at what you call tuck-ins or smaller acquisitions, which we can look at integrating with our existing business to get scale in the emerging markets," he added. The drug major has consistently indicated that it wants to remain disciplined about acquisition, Shanghvi said. "Our focus is on finding a way to grow our business organically at a rate so that we continue to be an attractive investment ...

Budget 2026: Customs duty relief to make cancer, rare disease drugs cheaper

A customs duty exemption on select high-cost cancer and rare disease therapies is expected to lower treatment costs for patients while supporting demand for multinational and domestic pharma companies

Budget 2026: Pharma dept prescribes PLI boost for bulk drug output

FY27 PLI scheme allocation rises 2.24%, aiming to add 500 MT to domestic API production

Budget 2026: Biopharma Shakti plan aims to make India a biologics hub

Union Budget 2026: Finance Minister Nirmala Sitharaman unveils Biopharma Shakti, a ₹10,000 crore, five-year plan to boost domestic biologics, biosimilars, clinical trials and regulatory capacity

Strides Pharma Q3FY26 results: Net profit doubles to ₹208.12 cr

Strides Pharma Science Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 208.12 crore in the third quarter ended December 31, 2025 on the back of robust sales growth and one time income on sale of property. The company had posted a consolidated net profit of Rs 90.04 crore in the corresponding quarter last fiscal, Strides Pharma Science Ltd said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,194.65 crore as against Rs 1,153.67 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 1,052.7 crore as compared to Rs 1,043.96 crore in the same period a year ago, the company said. The company said during the third quarter it sold its investment property consisting of land and building for a consideration of Rs 112.87 crore and recorded a profit of Rs 102.14 crore as other income. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur, ...

Q3FY26 preview: Strong domestic sales to lift revenues for pharma firms

Strong domestic sales are expected to lift Q3FY26 pharma revenues by 8-11%, while US generic Revlimid impacts weigh on margins. Hospitals and diagnostics outperform, with 20-22% revenue growth

Brazil, Nigeria emerging as key export destinations for Indian pharma firms

Brazil and Nigeria are emerging as key export destinations for Indian pharmaceutical firms amid global economic uncertainties, according to the commerce ministry data. Nigeria emerged as one of the fastest growing destinations, adding USD 179 million in exports and contributing over 14 per cent to the total export growth during the first eight months of this fiscal year. During April-November FY26, Brazil also recorded an increase of nearly USD 100 million exports, the data showed. "These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India's role as a preferred supplier to high growth demand intensive regions," an official said. The country's pharmaceutical exports rose by 6.5 per cent to USD 20.48 billion during April-November 2025-26. The data also showed that the US continues to be the single largest destination, accounting for over 31 per cent of exports in April-November 2025, while the overall gro